INTRODUCTION
• Multiple sclerosis (MS) is a chronic and degenerative neurological condition that is associated with neurological impairment, severe disability and premature mortality. 1 • In the Netherlands, the overall age-sex-standardized incidence rate of MS was 4.8 per 100,000 person-years and prevalence was estimated to be 1 in 1000 people. 2 • There are two broad categories for MS: relapsing disease and progressive disease. Relapsing disease is categorized in clinically isolated syndrome (CIS) and relapsing-remitting disease (RRMS). Over time, approximately 90% of patients with RRMS will develop Secondary Progressive disease (SPMS), a condition that bypasses the relapsing course of disease and is associated with fewer relapse events and a gradual progression in disability between relapses. 3 The RRMS phenotype is of primary interest for this poster, with special focus on the high disease activity (HDA) and rapidly evolving severe (RES) subpopulations.
• Recently, Cladribine Tablets have become available in the Netherlands for patients with RRMS, as a disease modifying drug (DMD) that reduces the frequency and severity of relapses and delays disability progression.
This study aimed to evaluate the cost-effectiveness of Cladribine Tablets compared to alemtuzumab and fingolimod in the treatment of RRMS patients with HDA and natalizumab in the treatment of patients with RES MS in the Netherlands.
METHODS
A previously developed Markov model 4 was adapted to simulate costs and effects of RRMS treatment in the Netherlands. Disease progression was modelled using the Kurtzke's Expanded Disability Status Scale (EDSS) system, for RRMS, SPMS and general mortality ( Figure 1) .
RESULTS

Deterministic sensitivity analysis
• A deterministic sensitivity analysis was performed with a threshold of €50,000 per QALY for both the HDA sub-population and the RES sub-population. Overall, the sensitivity analyses show robustness of the model, despite small parameter influences from disability progression. Probabilistic sensitivity analysis • For the HDA population, Cladribine Tablets was the dominant strategy when compared to alemtuzumab with a 50.9 % probability of being cost-effective at a threshold of €50,000 per QALY gained, and also when compared to fingolimod, with a 98.2% probability of being cost-effective at a threshold of €50,000 per QALY gained ( Figure 2 ). • For the RES population comparing against natalizumab, Cladribine Tablets was the dominant strategy with a 94.1% probability of being cost-effective at a threshold of €50,000 per QALY gained (Figure 2 ).
• The probabilistic sensitivity analyses showed significant overlap in the credible intervals for total lifetime QALY outcomes and costs of Cladribine Tablets and all relevant comparators. 
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DISCLOSURES
Merck B.V., the Netherlands provided funding to IQVIA for data acquisition and analysis. MK is a former employee and KS is employee of Merck B.V., Schiphol-Rijk, the Netherlands, an affiliate of Merck KGaA, Darmstadt, Germany. GH is employee of EMD Serono, Boston. The authors report no further conflicts of interest. In line with Dutch economic evaluation guidelines 4 , the model adopted a societal perspective, a lifetime horizon, and future costs and effects were discounted (1.5% and 4% respectively). Furthermore, a value-of-information (VOI) analysis was conducted. A VOI analysis quantifies the value of eliminating uncertainty around cost-effectiveness parameters. A VOI is mandatory in economic evaluations in the Netherlands. 4 In the HDA sub-population, Cladribine Tablets is the dominant option compared to alemtuzumab and fingolimod. Cladribine Tablets was also the dominant option compared to natalizumab in the RES subpopulation. 
Presented at ISPOR
Value-of-information analysis
The population-level VOI amounted to €19,295,441. NB: costs for each relapse were estimated at € 1,024. 
